Tivantinib(ARQ-197)isanorallybioavailablesmallmoleculeinhibitorofc-Metwithpotentialantineoplasticactivity.c-MetinhibitorARQ197bindstothec-Metproteinanddisruptsc-Metsignaltransductionpathways,whichmayinducecelldeathintumorcellsoverexpressingc-Metproteinorexpressingconsitutivelyactivatedc-Metprotein.c-Metprotein,theproductoftheproto-oncogenec-Met,isareceptortyrosinekinasealsoknownashepatocytegrowthfactorreceptor(HGFR);thisproteinisoverexpressedormutatedinmanytumorcelltypesandplayskeyrolesintumorcellproliferation,survival,invasion,andmetastasis,andtumorangiogenesis.

MedKooCat#:200283
Name:Tivantinib
CAS#:905854-02-6
ChemicalFormula:C23H19N3O2
ExactMass:369.14773
MolecularWeight:369.41
ElementalAnalysis:C,74.78;H,5.18;N,11.37;O,8.66


Synonym:ARQ197;ARQ197;ARQ-197;Tivantinib

IUPAC/ChemicalName:(3R,4R)-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione

InChiKey:UCEQXRCJXIVODC-PMACEKPBSA-N

InChiCode:InChI=1S/C23H19N3O2/c27-22-19(16-11-24-18-9-2-1-7-14(16)18)20(23(28)25-22)17-12-26-10-4-6-13-5-3-8-15(17)21(13)26/h1-3,5,7-9,11-12,19-20,24H,4,6,10H2,(H,25,27,28)/t19-,20-/m0/s1

SMILESCode:O=C([C@@H](C1=CN2CCCC3=C2C1=CC=C3)[C@@H]4C5=CNC6=C5C=CC=C6)NC4=O


TechnicalData

Appearance:
whitesolidpowder

Purity:
>98%(orrefertotheCertificateofAnalysis)

SafetyDataSheet(MSDS):
ViewMaterialSafetyDataSheet(MSDS)

ShippingCondition:
Shippedunderambienttemperatureasnon-hazardouschemical.ThisproductisstableenoughforafewweeksduringordinaryshippingandtimespentinCustoms.

StorageCondition:
Dry,darkandat0-4Cforshortterm(daystoweeks)or-20Cforlongterm(monthstoyears).

Solubility:
SolubleinDMSO,notinwater

ShelfLife:
>2yearsifstoredproperly

DrugFormulation:
ThisdrugmaybeformulatedinDMSO

StockSolutionStorage:
0-4Cforshortterm(daystoweeks),or-20Cforlongterm(months).

HarmonizedSystemCode:
293490


References

1:KangYK,MuroK,RyuMH,YasuiH,NishinaT,RyooBY,KamiyaY,AkinagaS,BokuN.AphaseIItrialofaselectivec-Metinhibitortivantinib(ARQ197)monotherapyasasecond-orthird-linetherapyinthepatientswithmetastaticgastriccancer.InvestNewDrugs.2013Dec15.[Epubaheadofprint]PubMedPMID:24337769.

2:PrevidiS,ScolariF,ChilàR,RicciF,AbbadessaG,BrogginiM.Combinationofthec-Metinhibitortivantinibandzoledronicacidpreventstumorboneengraftmentandinhibitsprogressionofestablishedbonemetastasesinabreastxenograftmodel.PLoSOne.2013Nov18;8(11):e79101.doi:10.1371/journal.pone.0079101.eCollection2013.PubMedPMID:24260160;PubMedCentralPMCID:PMC3832513.

3:RemsingRixLL,KuenziBM,LuoY,Remily-WoodE,KinoseF,WrightG,LiJ,KoomenJM,HauraEB,LawrenceHR,RixU.GSK3AlphaandBetaAreNewFunctionallyRelevantTargetsofTivantinibinLungCancerCells.ACSChemBiol.2013Nov20.[Epubaheadofprint]PubMedPMID:24215125.

4:YamamotoN,MurakamiH,HayashiH,FujisakaY,HirashimaT,TakedaK,SatouchiM,MiyoshiK,AkinagaS,TakahashiT,NakagawaK.CYP2C19genotype-basedphaseIstudiesofac-Metinhibitortivantinibincombinationwitherlotinib,inadvanced/metastaticnon-smallcelllungcancer.BrJCancer.2013Nov26;109(11):2803-9.doi:10.1038/bjc.2013.588.Epub2013Oct29.PubMedPMID:24169346;PubMedCentralPMCID:PMC3844902.

5:RimassaL,BruixJ,BrogginiM,SantoroA.Tivantinib(ARQ197)displayscytotoxicactivitythatisindependentofitsabilitytobindMET--letter.ClinCancerRes.2013Aug1;19(15):4290.doi:10.1158/1078-0432.CCR-13-1321.Epub2013Jun13.PubMedPMID:23766362.

6:MichieliP,BasilicoC,PennacchiettiS.Tivantinib(ARQ197)displayscytotoxicactivitythatisindependentofitsabilitytobindMET--response.ClinCancerRes.2013Aug1;19(15):4291.doi:10.1158/1078-0432.CCR-13-1534.Epub2013Jun13.PubMedPMID:23766360.

7:MichieliP,DiNicolantonioF.Targetedtherapies:Tivantinib--acytotoxicdruginMETinhibitor'sclothes?NatRevClinOncol.2013Jul;10(7):372-4.doi:10.1038/nrclinonc.2013.86.Epub2013May28.PubMedPMID:23712183.

8:KatayamaR,AoyamaA,YamoriT,QiJ,Oh-haraT,SongY,EngelmanJA,FujitaN.Cytotoxicactivityoftivantinib(ARQ197)isnotduesolelytoc-METinhibition.CancerRes.2013May15;73(10):3087-96.doi:10.1158/0008-5472.CAN-12-3256.Epub2013Apr18.PubMedPMID:23598276;PubMedCentralPMCID:PMC3759033.

9:BasilicoC,PennacchiettiS,VignaE,ChiriacoC,ArenaS,BardelliA,ValdembriD,SeriniG,MichieliP.Tivantinib(ARQ197)displayscytotoxicactivitythatisindependentofitsabilitytobindMET.ClinCancerRes.2013May1;19(9):2381-92.doi:10.1158/1078-0432.CCR-12-3459.Epub2013Mar26.PubMedPMID:23532890.

10:FeldmanDR,EinhornLH,QuinnDI,LoriotY,JoffeJK,VaughnDJ,FléchonA,HajdenbergJ,HalimAB,ZahirH,MotzerRJ.Aphase2multicenterstudyoftivantinib(ARQ197)monotherapyinpatientswithrelapsedorrefractorygermcelltumors.InvestNewDrugs.2013Aug;31(4):1016-22.doi:10.1007/s10637-013-9934-y.Epub2013Feb17.PubMedPMID:23417696.

11:RimassaL,PersoneniN,SimonelliM,SantoroA.Tivantinib:anewpromisingmesenchymal-epithelialtransitionfactorinhibitorinthetreatmentofhepatocellularcarcinoma.FutureOncol.2013Feb;9(2):153-65.doi:10.2217/fon.12.188.PubMedPMID:23414466.

12:YamamotoN,MurakamiH,NishinaT,HirashimaT,SugioK,MuroK,TakahashiT,NaitoT,YasuiH,AkinagaS,KohY,BokuN.TheeffectofCYP2C19polymorphismonthesafety,tolerability,andpharmacokineticsoftivantinib(ARQ197):resultsfromaphaseItrialinadvancedsolidtumors.AnnOncol.2013Jun;24(6):1653-9.doi:10.1093/annonc/mdt014.Epub2013Feb14.PubMedPMID:23413279.

13:BrogginiM,GarassinoMC,DamiaG.Evaluationofsafetyandefficacyoftivantinibinthetreatmentofinoperableorrecurrentnon-small-celllungcancer.CancerManagRes.2013;5:15-20.doi:10.2147/CMAR.S29995.Epub2013Jan17.PubMedPMID:23378782;PubMedCentralPMCID:PMC3559079.

14:SantoroA,SimonelliM,Rodriguez-LopeC,ZucaliP,CamachoLH,GranitoA,SenzerN,RimassaL,AbbadessaG,SchwartzB,LamarM,SavageRE,BruixJ.APhase-1bstudyoftivantinib(ARQ197)inadultpatientswithhepatocellularcarcinomaandcirrhosis.BrJCancer.2013Jan15;108(1):21-4.doi:10.1038/bjc.2012.556.Epub2013Jan3.PubMedPMID:23287988;PubMedCentralPMCID:PMC3553536.

15:SantoroA,RimassaL,BorbathI,DanieleB,SalvagniS,VanLaethemJL,VanVlierbergheH,TrojanJ,KolligsFT,WeissA,MilesS,GasbarriniA,LencioniM,CicaleseL,ShermanM,GridelliC,BuggischP,GerkenG,SchmidRM,BoniC,PersoneniN,HassounZ,AbbadessaG,SchwartzB,VonRoemelingR,LamarME,ChenY,PortaC.Tivantinibforsecond-linetreatmentofadvancedhepatocellularcarcinoma:arandomised,placebo-controlledphase2study.LancetOncol.2013Jan;14(1):55-63.doi:10.1016/S1470-2045(12)70490-4.Epub2012Nov20.PubMedPMID:23182627.

16:TrojanJ,ZeuzemS.Tivantinibinhepatocellularcarcinoma.ExpertOpinInvestigDrugs.2013Jan;22(1):141-7.doi:10.1517/13543784.2013.741586.Epub2012Nov21.Review.PubMedPMID:23167786.

17:WagnerAJ,GoldbergJM,DuboisSG,ChoyE,RosenL,PappoA,GellerJ,JudsonI,HoggD,SenzerN,DavisIJ,ChaiF,WaghorneC,SchwartzB,DemetriGD.Tivantinib(ARQ197),aselectiveinhibitorofMET,inpatientswithmicrophthalmiatranscriptionfactor-associatedtumors:resultsofamulticenterphase2trial.Cancer.2012Dec1;118(23):5894-902.doi:10.1002/cncr.27582.Epub2012May17.PubMedPMID:22605650.

18:GoldmanJW,LauxI,ChaiF,SavageRE,FerrariD,GarmeyEG,JustRG,RosenLS.Phase1dose-escalationtrialevaluatingthecombinationoftheselectiveMET(mesenchymal-epithelialtransitionfactor)inhibitortivantinib(ARQ197)pluserlotinib.Cancer.2012Dec1;118(23):5903-11.doi:10.1002/cncr.27575.Epub2012May17.PubMedPMID:22605616.

19:ScagliottiGV,NovelloS,SchillerJH,HirshV,SequistLV,SoriaJC,vonPawelJ,SchwartzB,VonRoemelingR,SandlerAB.RationaleanddesignofMARQUEE:aphaseIII,randomized,double-blindstudyoftivantinibpluserlotinibversusplacebopluserlotinibinpreviouslytreatedpatientswithlocallyadvancedormetastatic,nonsquamous,non-small-celllungcancer.ClinLungCancer.2012Sep;13(5):391-5.doi:10.1016/j.cllc.2012.01.003.Epub2012Mar21.PubMedPMID:22440336.

20:PrevidiS,AbbadessaG,DalòF,FranceDS,BrogginiM.Breastcancer-derivedbonemetastasiscanbeeffectivelyreducedthroughspecificc-METinhibitortivantinib(ARQ197)andshRNAc-METknockdown.MolCancerTher.2012Jan;11(1):214-23.doi:10.1158/1535-7163.MCT-11-0277.Epub2011Oct25.PubMedPMID:22027690.s